Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Comparison of the Effects of Kinesio Taping and Compression Bandaging on Edema, Range of Motion, Upper Extremity Function, and Grip Strength in Patients With Breast Cancer-Related Lymphedema

10 de noviembre de 2026 actualizado por: Halic University

This randomized crossover clinical trial aims to compare the effects of Kinesio Taping and compression bandaging on upper extremity edema, shoulder range of motion, upper extremity function, pain, and grip strength in patients with breast cancer-related lymphedema.

A total of 44 participants will receive both treatment approaches in different sequences. Each intervention period will last 4 weeks, with a 2-week washout period between treatments. Manual lymphatic drainage will be applied three times per week during the intervention periods. Assessments will be performed at baseline, week 4, and week 10.

Descripción general del estudio

Estado

Inscripción por invitación

Condiciones

Intervención / Tratamiento

Descripción detallada

This randomized crossover clinical trial was designed to compare the effects of Kinesio Taping and compression bandaging on upper extremity edema, shoulder range of motion, upper extremity function, pain, and grip strength in patients with breast cancer-related lymphedema.

A total of 44 participants will be randomly allocated to one of two treatment sequences. In the first 4-week treatment period, one group will receive Kinesio Taping combined with manual lymphatic drainage, while the other group will receive compression bandaging combined with manual lymphatic drainage. Manual lymphatic drainage will be administered three times per week during the intervention periods.

After completion of the first 4-week treatment period, a 2-week washout period will be implemented. Following the washout period, participants will cross over to the alternative intervention for an additional 4 weeks. Participants who initially received Kinesio Taping will subsequently receive compression bandaging, whereas participants who initially received compression bandaging will subsequently receive Kinesio Taping.

Clinical assessments will be performed at baseline, at the end of the first treatment period (week 4), and at the end of the second treatment period (week 10). Upper extremity edema, shoulder range of motion, upper extremity function, pain, and grip strength will be evaluated at these time points.

The crossover design allows all participants to receive both therapeutic interventions and enables within-participant comparison of the effects of Kinesio Taping and compression bandaging. The 2-week washout period is included to reduce potential carryover effects from the first treatment period before initiation of the second intervention.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

44

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Bakırköy
      • Istanbul, Bakırköy, Turquía (Türkiye), 34149
        • Istanbul University Cerrahpaşa Faculty of Medicine Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • Diagnosis of lymphedema following breast cancer treatment (confirmed by clinical evaluation or objective measurements).
  • Age between 18 and 75 years (adult participants will be included).
  • Willingness to participate voluntarily in the study and provision of written informed consent.
  • Unilateral lymphedema (to ensure standardization of assessments).
  • Lymphedema in the chronic stage (present for more than 3 months).
  • A stable condition in terms of lymphedema treatment (no other lymphedema treatment received within the last month).
  • Sufficient functional capacity to complete physical assessments and measurements (movement limitations should not be at a level that prevents evaluation).

Exclusion Criteria:

  • History of advanced-stage cancer or active metastatic disease.
  • Presence of severe cardiovascular or respiratory disease (e.g., heart failure, chronic obstructive pulmonary disease).
  • History of diabetic neuropathy or peripheral vascular disease (may affect lymphedema management due to circulatory impairment).
  • Presence of severe skin reactions or dermatological conditions (that compromise skin integrity and prevent tape application).
  • Pregnancy or breastfeeding.
  • History of allergic reactions to kinesio tape or compression bandages.
  • History of lymphatic drainage surgery or other surgical intervention within the past 6 months.
  • Diagnosis of bilateral lymphedema (only unilateral cases will be included to standardize the assessment process).
  • Inability to actively participate in the study due to mental or cognitive impairment.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Kinesiotaping Group

Patients with lymphedema who will receive kinesio taping treatment first, followed by compression bandaging.

MLD will accompany both groups throughout the intervention periods. MLD sessions will be administered by a trained physiotherapist three times per week for a total duration of 4 weeks in each treatment period.

Kinesio taping: This technique will be applied to the edematous extremity in accordance with lymphatic drainage directions, three times per week. The tapes will remain in place for 2-3 days at each application.

Compression bandaging: Multi-layer, short-stretch compression bandages will be reapplied after each MLD session (three times per week).

Due to the crossover design of the study, the applied interventions will be switched between groups after the initial 4-week treatment period. Prior to the second intervention phase, a 1-week washout period will be implemented to minimize potential carryover effects from the previous treatment. No treatment will be administered during this washout period.

Experimental: Compression Bandaging

Patients with lymphedema who will receive compression bandaging first, followed by kinesio taping treatment.

MLD will accompany both groups throughout the intervention periods. MLD sessions will be administered by a trained physiotherapist three times per week for a total duration of 4 weeks in each treatment period.

Kinesio taping: This technique will be applied to the edematous extremity in accordance with lymphatic drainage directions, three times per week. The tapes will remain in place for 2-3 days at each application.

Compression bandaging: Multi-layer, short-stretch compression bandages will be reapplied after each MLD session (three times per week).

Due to the crossover design of the study, the applied interventions will be switched between groups after the initial 4-week treatment period. Prior to the second intervention phase, a 1-week washout period will be implemented to minimize potential carryover effects from the previous treatment. No treatment will be administered during this washout period.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Upper Extremity Edema
Periodo de tiempo: The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Arm circumference measurement was used as an objective indicator of lymphedema severity. Circumferential measurements were obtained using a non-elastic tape measure at standardized anatomical landmarks along the upper extremity. Measurements were taken at fixed intervals (e.g., every 5 cm) starting from the wrist and progressing proximally toward the elbow and upper arm.

Values were recorded in millimeters (mm), with higher circumference values indicating greater edema severity. There is no predefined upper limit for arm circumference; therefore, larger measurements reflect increased fluid accumulation, whereas smaller values indicate reduced edema.

To quantify lymphedema, the difference in circumference between the affected and unaffected extremities was calculated at each measurement point. A greater inter-limb difference represents more severe lymphedema, while a reduction in this difference over time indicates clinical improvement.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.
Change in Pain Intensity
Periodo de tiempo: The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

The Visual Analog Scale (VAS) is a 10-centimeter horizontal line used to assess pain intensity. Scores range from 0 to 10, where 0 indicates no pain and 10 indicates worst imaginable pain. Higher scores indicate greater pain severity.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.
Change in Shoulder Range of Motion
Periodo de tiempo: The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Joint range of motion (ROM) was assessed to evaluate upper-extremity mobility in individuals with lymphedema. Active ROM measurements were obtained using a standard universal goniometer based on anatomical landmarks. Measurements were recorded in degrees (°) for wrist, elbow, forearm, and shoulder movements.

Higher ROM values indicate greater joint mobility and better functional status, whereas lower values reflect movement limitation. As ROM does not have a single fixed maximum value, results were interpreted relative to anatomical normative values and the contralateral limb.

A reduction of ≥10° compared with the unaffected side was considered a clinically meaningful limitation, while an increase toward normal values over time was interpreted as a positive treatment response. Each movement was measured three times, and the mean value was used for analysis. ROM assessments were performed at baseline and after each intervention period.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.
Change in Upper Extremity Function
Periodo de tiempo: The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Upper-extremity functioning was assessed using the Disabilities of the Arm, Shoulder and Hand (QuickDASH) Functioning Scale, a self-reported questionnaire designed to evaluate physical function and symptoms related to upper-limb disorders. The QuickDASH consists of 30 items, each scored on a 5-point Likert scale ranging from 1 (no difficulty) to 5 (unable to perform or extreme difficulty).

Item scores are combined and transformed into a total score ranging from 0 to 100, where 0 indicates no disability and 100 represents the most severe functional limitation. Higher scores therefore reflect worse upper-extremity functioning and greater disability.

A decrease in QuickDASH score over time indicates functional improvement, whereas an increase reflects worsening functional status. The QuickDASH has no absolute clinical cut-off; however, changes of 10-15 points are generally considered clinically meaningful.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.
Change in Grip Strength
Periodo de tiempo: The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Grip strength was assessed using a Jamar hand dynamometer, a widely accepted and reliable instrument for measuring isometric hand grip strength in clinical and research settings. Measurements were recorded in kilograms (kg), with higher values indicating greater muscle strength and better functional capacity, and lower values reflecting reduced grip strength.

Participants were seated in a standardized position with the shoulder adducted and neutrally rotated, the elbow flexed at 90 degrees, the forearm in a neutral position, and the wrist positioned between 0-30° extension and 0-15° ulnar deviation. Participants were instructed to squeeze the dynamometer with maximal effort for a few seconds. Each hand was tested three times, with adequate rest between trials to minimize fatigue, and the mean value was used for analysis.

The assessment measurements will be conducted before the initiation of treatment, after 4 weeks, and at week 10.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Seda Yildiz, PhD, Halic University

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

8 de febrero de 2026

Finalización primaria (Estimado)

1 de enero de 2027

Finalización del estudio (Estimado)

1 de abril de 2027

Fechas de registro del estudio

Enviado por primera vez

23 de febrero de 2026

Primero enviado que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Publicado por primera vez (Actual)

5 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de febrero de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 400

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

All data obtained from the assessment scales used in the study will be shared; however, patients' personal information, including names, surnames, and contact details, will be kept confidential. These personal data will only be shared on an individual basis if specifically requested.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • CIF
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .